Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Clopidogrel
Treatment for Lower extremity peripheral arterial disease
Typical Dosage: 75mg daily
Effectiveness
55%
Safety Score
72%
Clinical Trials
8
Participants
150K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
75mg daily
Time to Effect
Days for antiplatelet effect, long-term for CV event reduction
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$100
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$286
Comparison vs Aspirin
Cost Difference
+$130/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$360
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$100/year
Potential OTC Price
$50/year
Estimated if OTC available
Early Treatment Benefit
+0.08 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWClopidogrel Outcomes
for Lower extremity peripheral arterial disease
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+70%
Common Side Effects
Bleeding (non-major)
+5%
Major bleeding (e.g., GI hemorrhage)
+1%
Dyspepsia
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Clopidogrel in Lower extremity peripheral arterial disease
Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease
NCT06454045ACTIVE NOT RECRUITING
100 participants
OBSERVATIONAL
São Paulo, Brazil
Started: May 13, 2024
Vascular Trial Associated Registry Pilot
NCT07076082RECRUITINGPHASE4
350 participants
INTERVENTIONAL
Detroit, United States +1 more
Started: Oct 15, 2025
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
NCT07597239ACTIVE NOT RECRUITINGNA
130 participants
INTERVENTIONAL
Boston, United States
Started: Dec 14, 2022
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
NCT06873321RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Pernambuco, Brazil
Started: Feb 24, 2024
Completed Clinical Trials
2 completed trials for Clopidogrel in Lower extremity peripheral arterial disease
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
NCT02217501COMPLETEDPHASE3
159 participants
INTERVENTIONAL
Denver, United States +3 more
Started: Nov 1, 2015
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
NCT00687076COMPLETEDPHASE4
102 participants
INTERVENTIONAL
Houston, United States
Started: Apr 1, 2004